Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are 7 medtech stories we missed this week, but were still worth mentioning. 1. Insulet touts glucose control study Insulet Corp. announced the results from its first feasibility study of its Omnipod […]
Insulet
Insulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D
Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe. The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes […]
Insulet opens manufacturing facility in Acton, Mass.
Insulet (NSDQ:PODD) said yesterday that it acquired a manufacturing facility in Acton, Mass. The Billerica, Mass.-based company said that its new facility will allow Insulet to more efficiently manufacture its OmniPod system compared to 4 of the company’s manufacturing lines at its contract manufacturer in China. The company anticipates the new facility will add hundreds of jobs in Massachusetts […]
Insulet posts beat-and-raise Q3
Shares in Insulet (NSDQ:PODD) are soaring in after-hours trading after the diabetes device developer posted Street-beating 3rd quarter earnings and raised its guidance for the rest of the year. The Billerica, Mass.-based company posted losses of $3.1 million, or 5¢ per share, on sales of $94.9 million. That equates to an 83.7% reduction in losses while sales […]
LimFlow taps Rose for CEO | Personnel Moves
LimFlow taps ex-Direct Flow GM Rose as CEO LimFlow said this week that it tapped former Direct Flow Medical VP and GM Daniel Rose as its new chief executive, with former co-founder & CEO Timothy Lenihan transitioning to chief technology officer. LimFlow is developing a device to create percutaneous venous arterialization in the foot to treat end-stage critical limb […]
Analyst: Insulet’s drug-delivery biz a long-term growth driver
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to […]
Insulet closes $345 private placement
Insulet (NSDQ:PODD) said yesterday that it closed a $345 million private placement, raking in $45 million more than it expected when it priced the round last week. Billerica, Mass.-based Insulet, which makes the Omnipod insulin management system for treating diabetes, said it closed a private placement of $345 million principal amount in convertible senior notes, due […]
Insulet launches artificial pancreas feasibility trial for Omnipod Horizon device
Insulet (NSDQ:PODD) said today that it’s launching a clinical trial of an artificial pancreas system based on its flagship Omnipod insulin management device for treating Type I diabetes. The Omnipod Horizon automated glucose control system will link the Omnipod with continuous glucose monitoring technology from DXCM, Billerica, Mass.-based Insulet said. The 20-patient trial is designed to […]
Insulet lifts debt offering to $300m
Insulet (NSDQ:PODD) today released pricing for its previously announced debt offering, increasing the principal amount from $250 million to $300 million. Billerica, Mass.-based Insulet, which makes the Omnipod insulin management system for treating diabetes, said it priced a private placement of $300 million principal amount in convertible senior notes, due 2021, with an annual interest rate […]
Insulet plans $250m debt offering
Insulet (NSDQ:PODD) said yesterday that it plans to fund a new, automated U.S. plant in part with the proceeds from a $250 million debt offering. Billerica, Mass.-based Insulet, which makes the Omnipod insulin management system for treating diabetes, said the private placement offering of senior notes due in 2021 includes an option on another $37.5 million worth […]
Insulet taps ATS Automation Tooling for planned U.S. plant, beefs up executive suite
Insulet (NSDQ:PODD) said today it inked a 5-year deal with ATS Automation Tooling Systems to construct an automated manufacturing assembly line for its products and announced a pair of new executive appointments. Get the full story at our sister site, Medical Design & Outsourcing.